

# Keishi Makino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4601224/publications.pdf>

Version: 2024-02-01

22  
papers

620  
citations

623574

14  
h-index

752573

20  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1274  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border. <i>EBioMedicine</i> , 2018, 30, 94-104.	2.7	77
2	Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. <i>Annals of Nuclear Medicine</i> , 2011, 25, 432-438.	1.2	76
3	Population-based epidemiological study of primary intracranial tumors in childhood. <i>Child's Nervous System</i> , 2010, 26, 1029-1034.	0.6	74
4	Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. <i>Acta Neuropathologica Communications</i> , 2018, 6, 134.	2.4	74
5	Quality of Life and Clinical Features of Long-Term Survivors Surgically Treated for Pediatric Craniopharyngioma. <i>World Neurosurgery</i> , 2016, 85, 153-162.	0.7	51
6	Machine learning based on multi-parametric magnetic resonance imaging to differentiate glioblastoma multiforme from primary cerebral nervous system lymphoma. <i>European Journal of Radiology</i> , 2018, 108, 147-154.	1.2	41
7	Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan. <i>World Neurosurgery</i> , 2006, 66, 503-506.	1.3	40
8	Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. <i>Journal of Neuro-Oncology</i> , 2012, 106, 155-160.	1.4	37
9	A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma. <i>Neuropathology</i> , 2016, 36, 181-186.	0.7	22
10	Ectopic adrenal cortical adenoma in the spinal region: case report and review of the literature. <i>Brain Tumor Pathology</i> , 2010, 27, 121-125.	1.1	20
11	Clinical characteristics and pathogenesis of cerebellar glioblastoma. <i>Molecular Medicine Reports</i> , 2014, 10, 2383-2388.	1.1	19
12	Novel metal chelating molecules with anticancer activity. Striking effect of the imidazole substitution of the histidine-pyridine-histidine system. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5476-5482.	1.4	18
13	Differentiating Between Primary Central Nervous System Lymphomas and Glioblastomas: Combined Use of Perfusion-Weighted and Diffusion-Weighted Magnetic Resonance Imaging. <i>World Neurosurgery</i> , 2018, 112, e1-e6.	0.7	18
14	BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 115-121.	1.4	16
15	Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience. <i>International Journal of Clinical Oncology</i> , 2015, 20, 29-34.	1.0	15
16	Fatty acid synthase is a predictive marker for aggressiveness in meningiomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 399-404.	1.4	9
17	Clinical significance of polyglutamylation in primary central nervous system lymphoma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 15.	2.4	5
18	Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma. <i>Oncology Letters</i> , 2017, 14, 264-270.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Additive Value of 3T 3D CISS Imaging to Conventional MRI for Assessing the Abnormal Vessels of Spinal Dural Arteriovenous Fistulae. <i>Magnetic Resonance in Medical Sciences</i> , 2018, 17, 218-222.	1.1	3
20	Benefit of 3T Diffusion-weighted Imaging in Comparison to Contrast-enhanced MR Imaging for the Evaluation of Disseminated Lesions in Primary Malignant Brain Tumors. <i>Magnetic Resonance in Medical Sciences</i> , 2017, 16, 217-222.	1.1	2
21	ML-03 RECONSIDERATION OF TREATMENT FOR ELDERLY PATIENTS WITH PRIMARY CENTRAL NERVE SYSTEM LYMPHOMAS. <i>Neuro-Oncology Advances</i> , 2019, 1, ii32-ii32.	0.4	0
22	ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL). <i>Neuro-Oncology Advances</i> , 2020, 2, ii17-ii17.	0.4	0